ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

AACI Seeks Change In Cancer Act To Bypass Study Sections On Small Grants With Review By NCAB

March 5, 1982

Nader Group Backs FDA In controversy Over Drug Testing

February 11, 1977

Biological Modifiers Journal Objects To NEJ Policy, Says It Will OK Clinical Data Release

April 26, 1985

FDA Approves Implant For Breast Reconstruction

July 26, 2013

High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial

November 28, 2008

FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA

July 3, 1981